PL4277628T3 - Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego - Google Patents

Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego

Info

Publication number
PL4277628T3
PL4277628T3 PL22700096.5T PL22700096T PL4277628T3 PL 4277628 T3 PL4277628 T3 PL 4277628T3 PL 22700096 T PL22700096 T PL 22700096T PL 4277628 T3 PL4277628 T3 PL 4277628T3
Authority
PL
Poland
Prior art keywords
tasquinimod
treatment
pharmaceutically acceptable
acceptable salt
myelodysplastic syndrome
Prior art date
Application number
PL22700096.5T
Other languages
English (en)
Polish (pl)
Inventor
Manja WOBUS
Katja SOCKEL
Martin BORNHÄUSER
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of PL4277628T3 publication Critical patent/PL4277628T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL22700096.5T 2021-01-18 2022-01-17 Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego PL4277628T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21201509 2021-10-07
EP21205665 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
PL4277628T3 true PL4277628T3 (pl) 2026-02-09

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22700096.5T PL4277628T3 (pl) 2021-01-18 2022-01-17 Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego

Country Status (12)

Country Link
US (1) US20240091215A1 (enExample)
EP (1) EP4277628B1 (enExample)
JP (1) JP7837338B2 (enExample)
KR (1) KR20230133317A (enExample)
AU (1) AU2022208424A1 (enExample)
CA (1) CA3204120A1 (enExample)
ES (1) ES3057099T3 (enExample)
IL (1) IL304232A (enExample)
MX (1) MX2023008016A (enExample)
PL (1) PL4277628T3 (enExample)
WO (1) WO2022152902A1 (enExample)
ZA (1) ZA202307855B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240012436A (ko) 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome
CN122272585A (zh) * 2026-05-08 2026-06-26 吉林大学 他喹莫德在制备用于调控淋巴管炎症反应的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
SI3016512T1 (sl) 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)
SG11201607083VA (en) 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP3041472B1 (en) * 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017009854B1 (pt) 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
JP2019127473A (ja) 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
US20240091215A1 (en) 2024-03-21
ES3057099T3 (en) 2026-02-26
EP4277628A1 (en) 2023-11-22
AU2022208424A9 (en) 2024-05-09
EP4277628C0 (en) 2025-09-24
CA3204120A1 (en) 2022-07-21
AU2022208424A1 (en) 2023-08-24
ZA202307855B (en) 2025-12-17
MX2023008016A (es) 2023-07-13
EP4277628B1 (en) 2025-09-24
KR20230133317A (ko) 2023-09-19
JP7837338B2 (ja) 2026-03-30
JP2024503372A (ja) 2024-01-25
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
RS67775B1 (sr) Kombinovana terapija koja uključuje inhibitor kras-g12c i jedan ili više dodatnih farmaceutski aktivnih agenasa za lečenje kancera
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL190284A (en) Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
PL3676285T3 (pl) Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby
IL304232A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL3829628T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
IL236041A (en) 1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseases
LT3697399T (lt) Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
IL272562B1 (en) Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection
IL295014B1 (en) A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma
IL304737A (en) Dangapetide for the treatment or prevention of kidney disease
ZA202101652B (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
GB202002299D0 (en) Agents for use in the treatment of tissue damage
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
GB2625845B (en) Ophiopogonin D for use in the treatment caused by rotavirus infection
IL286029A (en) Potassium binding agents for use in hemodialysis patients
IL310580A (en) RALOXIFENE for use in the treatment of SARS-COV-2 infections
GB202314713D0 (en) Novel adamantyl derivative or pharmaceutically acceptable salt thereof, and use thereof
PH32020050509S1 (en) Therapeutic pillow
FIC20200030I1 (fi) Krisaboroli, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa